A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.A. Jo Chien, Andrei Goga, Melanie Majure et al.|Journal of Clinical Oncology|2020Cited by 19
Inhalt, Vol. 17, No. 1, 1994G. Maschmeyer, Andreas Obermair, W. Hiddemann et al.|Onkologie|2009Cited by 0